It is a well-known fact that where there is stem cell transplantation, there is Graft vs Host Disease (GVHD). The concept arose 2 decades ago and is not rare- it is a common complication of allogen...
Roche's drug candidate for Multiple Sclerosis touted to be better than Merck’s Rebif The much anticipated multiple sclerosis drug from Roche, ocrelizumab, has overtaken Merck’s Rebif according to the results of Phase III data, and has also shown great stats that could prove that it might have an edge in the hotly co...
Find More
Targeted treatment can become a reality for esophageal cancer, as a study opens door A group of researchers Scientists, funded by Cancer Research UK and Medical Research Council, have discovered that oesophageal cancer can be classified into three different subtypes, paving the way for testing targeted treatments ta...
Find More
Game changing agent, Opdivo, on a threshold to change standard of care in squamous cell carcinoma of the head and neck (SCCHN) According to Dr. Robert Ferris, who is vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of ...
Find More
The South San Francisco biotech startup, Denali Therapeutics, that had raised $217 million last year to fight Alzheimer’s, Parkinson’s and ALS, and an additional $130 million from investors in a private placement led by Baillie Gifford, a UK-based mutual fund, has finally spoken about its plans to use the fund. The...
Find More
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats), a gene-editing technology, has set a record by reaching clinics from the research laboratory in a very short time, as NIH’s Recombinant DNA Advisory Committee has approved the first clinical trial of the technology in the U.S. for coming June. The t...
Find More
To download the pdf version of the Newsletter: Click the following DelveInsight Newsletter
Find More
Spinal Muscular Atrophy (SMA) is a rare genetic and neuromuscular condition which affects mainly children. It has several distinct types such as type 1 (Werdnig-Hoffmann disease), type 2 (Dubowitz disease), type 3 (Kugelberg-Welander disease) and type 4 (Adult onset). SMN1 (Survival Motor Neuron 1) is the primary ge...
Find More
For over 100 years, immunotherapy has played a significant role in the treatment of cancer. Immune stimulatory agents such as Toll-like receptor (TLR) agonists, adoptive T cell and natural killer (NK) cell therapies, cytokine-based therapies etc. have gained approval for treatment of various indications. In 1980s, r...
Find More
According to DelveInsight researchers, the Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020. DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2...
Find More
The most common lysosomal disease, Gaucher Disease is a result of lack of sufficient glucocerebrosid.....
Find More-Agonist.png)
Toll-like Receptors (TLRs) are a type of pattern recognition receptor (PRR) that recognizes pathogen.....
Find More
Sepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Se.....
Find More
The medical device industry is experiencing rapid change as innovation is accelerating, new business.....
Find More-Feature.png)
Gastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....
Find More
Systemic scleroderma (SSC or systemic sclerosis) is an autoimmune disorder that results into scar ti.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
